NCT07217119View on ClinicalTrials.gov

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 26, 2019

Primary Completion Date

April 17, 2025

Study Completion Date

March 11, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered.

DRUG

Feladilimab

Feladilimab will be administered.

Trial Locations (11)

3000

GSK Investigational Site, Melbourne

3065

GSK Investigational Site, Fitzroy

22083

GSK Investigational Site, Hamburg

30322

GSK Investigational Site, Atlanta

31008

GSK Investigational Site, Pamplona Navarra

53792

GSK Investigational Site, Madison

94805

GSK Investigational Site, Villejuif

V5Z1M9

GSK Investigational Site, Vancouver

M5G2M9

GSK Investigational Site, Toronto

3584CX

GSK Investigational Site, Utrecht

SE-141 86

GSK Investigational Site, Stockholm

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT07217119 - Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM | Biotech Hunter | Biotech Hunter